Koers Benitec Biopharma Inc. Deutsche Boerse AG
Aandelen
BJ9
US08205P2092
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,06 EUR | -2,70% | -.--% | -.--% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 105 mln. 69,33 mln. 64,51 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,95
x | K/w-verhouding 2025 * |
-8,33
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,72% |
1 dag | -2,70% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 01-10-16 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-15 |
Megan Boston
CMP | Compliance Officer | 52 | 01-08-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 01-04-13 |
Edward Smith
BRD | Director/Board Member | 53 | 14-04-20 |
Peter Francis
BRD | Director/Board Member | 68 | 01-02-06 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+49,41% | 56,95 mld. | |
+39,53% | 40,26 mld. | |
-6,72% | 39,32 mld. | |
-5,96% | 28,37 mld. | |
+12,99% | 26,45 mld. | |
-19,82% | 19,41 mld. | |
+32,35% | 12,54 mld. | |
-0,08% | 12,15 mld. | |
+25,18% | 12,21 mld. |
- Beurs
- Aandelen
- Koers BNTC
- Koers BJ9